Overview

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

Status:
Active, not recruiting

Trial end date:
2022-11-22

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Androgens